

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED
UNINTENTIONALLY UNDER 37 CFR 1.137(b)**Docket Number (Optional)
PK4835First named inventor: **Melissa E. Scott**Application No.: **09/828,072**Group Art Unit: **1636**Filed: **April 6, 2001**

Examiner:

Title: **HIGH-THROUGHPUT SCREENING ASSAYS BY ENCAPSULATION**

Attention: Office of Petitions
Assistant Commissioner for Patents
Box DAC
Washington, D.C. 20231

NOTE: If information or assistance is needed in completing this form, please contact Petitions
Information at (703) 305-9282.

The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the Office notice or action plus any extensions of time actually obtained.

APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:

- (1) Petition fee;
- (2) Reply and/or issue fee;
- (3) Terminal disclaimer with disclaimer fee --required for all utility and plant applications filed before June 8, 1995; and for all design applications; and
- (4) Statement that the entire delay was unintentional.

1. Petition fee

 Small entity-fee \$ _____ (37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27. Other than small entity - fee \$ 1,280 (37 CFR 1.17(m))

2. Reply and/or fee

A. The reply and/or fee to the above-noted Office action in the form of Declaration and Power of Attorney (identify type of reply):
 has been filed previously on _____.
 is enclosed herewith.

B. The issue fee of \$ _____.
 has been paid previously on _____.
 is enclosed herewith.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 1.0 hour to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

08/28/2002 AWONDAF1 00000150 071392 09828072

01 FC:141 1280.00 CH

RECEIVED

AUG 29 2002

Express Mail Label No.
EV022027288US**OFFICE OF PETITIONS**

3. Terminal disclaimer with disclaimer fee

Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.

A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ _____ for a small entity or \$ _____ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).

4. STATEMENT: The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional. [NOTE. The United States Patent and Trademark Office may require additional information if there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137(b) was unintentional (MPEP 711.03(c)(III)(C) and (D))].

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

August 26, 2002

Date



Signature

Telephone

Number: (919) 483-2482

Frank P. Grassler, Reg. 31,164

Typed or printed name

GlaxoSmithKline

Address

Five Moore Drive, RTP, NC 27709

Enclosures: Fee Payment

Reply

Terminal Disclaimer Form

Additional sheets containing statements establishing unintentional delay

Other: _____

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]

I hereby certify that this correspondence is being:


deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Box DAC, Washington, D.C. 20231.

transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) 308-6916.

Date

Signature

Type or printed name of person signing certificate



#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of: SCOTT et al.

Serial No.: 09/828,072

Group Art Unit: 1636

Filed: April 6, 2001

Examiner:

For: *High-Throughput Screening
Assays By Encapsulation*

BOX DAC
Commissioner for Patents
Washington, D.C. 20231

RENEWED PETITION UNDER 37 CFR 1.137(b)

Applicants request reconsideration of the Decision Dismissing Petition under 37 CFR 1.137(b), date mailed July 5, 2002, and request the attached renewed Petition for Revival of an Application for Patent Abandoned Unintentionally be granted.

The above-identified application became abandoned for failure to respond in a timely manner to the Notice to File Missing Parts, date mailed June 4, 2001, which set a shortened statutory period for reply of two (2) months. In accordance with the requirements of 37 CFR 1.137(b), Applicants submit the following:

1. A Declaration and Power of Attorney in reply to the outstanding Notice to File Missing Parts.
2. The petition fee as set forth in § 1.17(m)
3. A statement that the entire delay in filing the required reply was unintentional.
4. A Change of Correspondence Address

Should the Examiner have any questions or concerns regarding the above, Applicants' attorney can be contacted at the number listed below.

09/11/2002 AKELLEY 0000012 071392 09828072

01 FC:122

130.00 CH

Respectfully submitted,


Frank P. Grassler
Attorney of Record
Registration No. 31,164

Date: August 26, 2002

GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483- 2482
Facsimile: (919) 483-7988



23347

PATENT TRADEMARK OFFICE

RECEIVED

AUG 29 2002

Express Mail Label No.
EV022027288US

OFFICE OF PETITIONS